Gilead Sciences to acquire Kite Pharma for $11.9bn

Adjust Comment Print

As per Tuesday, June 27, the company rating was maintained by Canaccord Genuity.

KITE has been the subject of a number of other reports. The short interest to Kite Pharma Incorporated's float is 22.2%.

In other news, EVP Helen Susan Kim sold 79,949 shares of the firm's stock in a transaction on Tuesday, August 8th. Sandy Spring Commercial Bank owns 1,100 shares. The SI to Medidata Solutions Incorporated's float is 6.45%. About shares traded. Federal Realty Investment Trust (FRT) has declined 16.62% since August 29, 2016 and is downtrending. (NASDAQ:GILD). Brown Management Ltd Liability has invested 0.02% in Gilead Sciences, Inc. It has outperformed by 51.67% the S&P500. It increased, as 106 investors sold GILD shares while 656 reduced holdings. It also upped Allstate Corp (NYSE:ALL) stake by 10,055 shares and now owns 63,045 shares. (NASDAQ:GILD). Wunderlich Managemnt holds 0.74% or 12,678 shares in its portfolio. Hall Laurie J Trustee has 60 shares for 0% of their portfolio. Axiom Int Invsts De holds 35,086 shares. Nuveen Asset Management Limited Co holds 504,129 shares. Shares for $1.17 million were bought by Belldegrun Arie. Janney Montgomery Scott Limited Liability Com holds 298,010 shares. (NASDAQ:GILD). Bluecrest Mgmt has 0.02% invested in Gilead Sciences, Inc. The Switzerland-based Credit Suisse Ag has invested 0% in Kite Pharma Inc (NASDAQ:KITE). (NASDAQ:GILD). Alpine Woods Invsts Lc has 31,600 shares for 0.13% of their portfolio. Duncker Streett Co Inc has 0.08% invested in Gilead Sciences, Inc. The total amount of shares outstanding is 1.31 billion, giving the company a market capitalization of about 96.66 billion. It has a 8.55 P/E ratio.

Spectral Medical Inc., formerly Spectral Diagnostics Inc., is a therapeutic development company.

US Open 2017: Staying at the top is hardest, says Angelique Kerber
The contrast to 12 months ago could not have been more stark, but she said: "I'm still the same player and the same person". It was a little bit hard , but I think I made it pretty okay today.

Since March 2, 2017, it had 0 buys, and 6 sales for $2.28 million activity. Alton Gregg H also sold $337,392 worth of Gilead Sciences, Inc. 5,000 shares were sold by Capone Michael L, worth $347,300 on Monday, May 15. On Thursday, November 12 the stock rating was maintained by Investec with "Buy". The insider TAYLOR ROBERT sold $414,241. Therefore 40% are positive. Melcor Developments had 6 analyst reports since August 14, 2015 according to SRatingsIntel. Creative Planning accumulated 13,207 shares. The firm has "Hold" rating by Maxim Group given on Friday, April 29. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The rating was downgraded by Wedbush to "Underperform" on Tuesday, May 9. Vanguard Group Inc. now owns 3,661,547 shares of the biopharmaceutical company's stock valued at $287,395,000 after buying an additional 507,289 shares in the last quarter. The firm has "Outperform" rating given on Wednesday, February 3 by RBC Capital Markets. In the first quarter, Gilead had said it wanted to do a deal in cancer, and analysts suggested Kite, Incyte (INCY), Tesaro (TSRO) and Clovis Oncology (CLVS) could be on the list. Can boosted its position in shares of Kite Pharma by 28.1% in the first quarter. Gilead Sciences has a consensus rating of "Buy" and an average price target of $80.64. Old Mutual Glob (Uk) Ltd reported 518,969 shares. Menora Mivtachim stated it has 2.9% of its portfolio in Kite Pharma Inc (NASDAQ:KITE). It has underperformed by 38.50% the S&P500.

Investors sentiment decreased to 0.82 in 2016 Q4. Its down 0.21, from 1.45 in 2016Q3.

The Kite acquisition answers critics who have questioned Gilead's sluggishness in moving on a transformative deal. Guardian Tru reported 463,700 shares. Notis has 0.7% invested in Gilead Sciences, Inc. Alps Advsr holds 0.02% or 47,930 shares. Stifel Nicolaus reiterated a hold rating and issued a $74.00 price target on shares of Kite Pharma in a research report on Thursday, August 10th. Morgan Stanley reported 0% stake. National Bank & Trust Of Nova Scotia invested 0.03% of its portfolio in Gilead Sciences, Inc. Dimensional Fund Ltd Partnership invested in 0.01% or 598,939 shares. D E Shaw And, New York-based fund reported 10,282 shares. Renaissance Gru Llc owns 183,845 shares.

Net income in the quarter soared 26.9% to $114.2 million or $1.83 per diluted share from $90 million or $1.43 in the same quarter past year.